Home/Pipeline/Cell Delivery & Transplantation Platform

Cell Delivery & Transplantation Platform

Potential for Type 1 Diabetes (Islet Transplantation), Soft Tissue Reconstruction

ResearchActive

Key Facts

Indication
Potential for Type 1 Diabetes (Islet Transplantation), Soft Tissue Reconstruction
Phase
Research
Status
Active
Company

About Graftable

Graftable is an early-stage biotech focused on tissue engineering for improved injury repair. The company's mission is to enable faster healing with less scarring and tissue loss, targeting significant unmet needs in post-traumatic, post-surgical, and post-cancer resection wound care. While still in a pre-clinical/pre-revenue stage, its platform technology holds promise for both aesthetic/functional skin repair and complex cell transplantation. The company appears to be privately held and in a foundational phase of technology development.

View full company profile